This article was originally published in Start Up
Drug Discovery Tools; Genomics. Sequenom combines mass spectrometry, DNA conditioning chemistry, and a patented DNA chip to identify and analyze high volumes of DNA with great accuracy. The technology measures the molecular weight of DNA samples to reveal disease-causing molecules.
You may also be interested in...
Germany is addressing its problems of lack of management and capital for start-up biotechs.
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
Pharma companies are building long-term value propositions that should appeal to Accountable Care Organizations into some go-to-market strategies for new drugs and to repositioning efforts of already marketed drugs that have hit snags. The rationale might seem straightforward—for example, more convenient dosing that improves compliance and cuts down hospitalization rates--but the nuances can be complex. Moreover, even when their products appear to have compelling cases for value, companies have not by and large made ACOs a distinct target for their commercial operations.